Novartis
NVS
NVS
919 hedge funds and large institutions have $21.7B invested in Novartis in 2017 Q2 according to their latest regulatory filings, with 84 funds opening new positions, 308 increasing their positions, 361 reducing their positions, and 58 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
1% more funds holding
Funds holding: 908 → 919 (+11)
0.26% less ownership
Funds ownership: 11.36% → 11.09% (-0.26%)
15% less repeat investments, than reductions
Existing positions increased: 308 | Existing positions reduced: 361
Holders
919
Holding in Top 10
40
Calls
$65M
Puts
$40.8M
Top Buyers
| 1 | +$159M | |
| 2 | +$121M | |
| 3 | +$71.6M | |
| 4 |
BlackRock
New York
|
+$59.9M |
| 5 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$45.8M |
Top Sellers
| 1 | -$176M | |
| 2 | -$114M | |
| 3 | -$108M | |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$98.6M |
| 5 |
Renaissance Technologies
New York
|
-$82.1M |